VONVENDI treatment for adults in China with von Willebrand disease

A Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in the Treatment of Bleeding Episodes in Chinese Subjects Diagnosed With Von Willebrand Disease

We will test whether VONVENDI is safe and helps control bleeding in adult Chinese patients with severe von Willebrand disease, sometimes given with ADVATE if their factor VIII is low.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Takeda (Industry-sponsored)
• Drugs / interventions: chemotherapy
• Locations: 7 sites (Beijing and 6 other locations)
• Trial ID: NCT07129343 on ClinicalTrials.gov

What this trial studies

Adult Chinese participants with severe VWD will receive an initial dose of VONVENDI (40–80 IU/kg), and those with low baseline FVIII may also receive 30–45 IU/kg of ADVATE. The trial tracks safety, bleeding control around elective surgeries or dental procedures, and measures how VONVENDI is processed in the body (PK) and its biological effects (PD). Participants will be followed for about 14 months with clinic visits and telephone follow‑up. This is a phase 3 interventional study conducted at several hospitals in China.

Who should consider this trial

Good fit: Adults (age ≥18) in China with documented severe von Willebrand disease (for example VWF:RCo <20 IU/dL or type 3) who can give informed consent are the intended participants.

Not a fit: People without severe VWD, those under 18, or those unable to comply with study visits and follow‑up are unlikely to benefit from this trial.

Why it matters

Potential benefit: If successful, VONVENDI could provide a safe, effective replacement therapy to reduce bleeding and support procedures in adults with severe VWD.

How similar studies have performed: Recombinant VWF products such as VONVENDI have demonstrated efficacy and an acceptable safety profile in prior international studies, though data specifically in Chinese adults are limited.

Eligibility criteria

Inclusion Criteria

1. Participant must voluntarily sign an institutional review board (IRB)/independent ethics committee-approved written informed consent form after all relevant aspects of the study have been explained and discussed with the participant.
2. Participant has a documented diagnosis of severe VWD (baseline VWF:RCo less than \[\<\]20 international units \[IU\]deciliter \[dL\]) with a diagnosis of VWD type verified per the following recommended criteria:

   * Type 1 (von Willebrand factor:Ristocetin cofactor activity \[VWF:RCo\] \<20 IU/dL and by VWF activity/VWF:antigen \[Ag\] ratio) or,
   * Type 2A or type 2B (by VWF activity/VWF:Ag ratio and multimer pattern, with genetics if necessary), type 2N (FVIII:C \<10% and genetics), type 2M (by VWF activity/VWF:Ag ratio and multimer pattern) or
   * Type 3 (VWF:Ag \<=3 IU/dL). Diagnosis is confirmed, when applicable, by genetic testing and/or by multimer analysis.
3. Participant is at least 18 years of age at screening.
4. Participant is ethnic Chinese and lives in China, including those from Taiwan, Hong Kong, and Macao.
5. If female of childbearing potential, participant presents with a negative pregnancy test and agrees to employ adequate birth control measures for the duration of the study.
6. Participant is willing and able to comply with the requirements of the protocol.
7. Participant has had a minimum of 3 documented bleeds that indicated the need for VWF coagulation factor replacement therapies during the previous 12 months prior to enrollment.

Exclusion Criteria

1. Participant has been diagnosed with pseudo VWD or another hereditary or acquired coagulation disorder other than VWD (example \[eg\], qualitative and quantitative platelet disorders or elevated prothrombin time \[PT\]/international normalized ratio \>1.4).
2. Participant has a history or presence of a VWF inhibitor at screening.
3. Participant has a documented history of a VWF:RCo half-life of \<6 hours.
4. Participant has a history or presence of a FVIII inhibitor with a titer greater than or equal to \[\>=\] 0.6 Bethesda units per milliliter \[BU/mL\] (by Bethesda assay or Bethesda method with Nijmegen modification).
5. Participant has a known hypersensitivity to any of the components of the study drugs, such as to mouse or hamster proteins.
6. Participant has a medical history of immunological disorders, excluding seasonal allergic rhinitis/conjunctivitis, mild asthma, food allergies or animal allergies.
7. Participant has a medical history of a thromboembolic event.
8. Participant is human immunodeficiency virus (HIV) positive with an absolute cluster of differentiation 4 (CD4) count \<200/cubic millimeter (mm\^3).
9. Participant has been treated with an immunomodulatory drug, other than antiretroviral chemotherapy eg, α-interferon, or corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 milligram (mg)/day (excluding topical treatment \[eg, ointments, nasal sprays\]), within 30 days prior to signing the informed consent (or assent, if appropriate).
10. Participant is pregnant or lactating at the time informed consent is obtained.
11. Participant has participated in another clinical study involving an IP, or investigational device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an IP or investigational device during the course of this study.
12. Participant is diagnosed with progressive fatal disease and/or has a life expectancy of less than 15 months.
13. Participant is member of the study team conducting this study or in a dependent relationship with one of the study team members. Dependent relationships include close relatives (that is, children, partner/spouse, siblings, parents) as well as employees.
14. Participant has an acute illness (eg, influenza, flu-like syndrome, allergic rhinitis/conjunctivitis, nonseasonal asthma) at screening.
15. Participant is diagnosed with significant liver disease, as evidenced by, but not limited to, any of the following: serum alanine aminotransferase (ALT) greater than 5 times the upper limit of normal; hypoalbuminemia; portal vein hypertension (eg, presence of otherwise unexplained splenomegaly, history of esophageal varices) or liver cirrhosis classified as Child-Pugh class B or C.
16. Participant has been diagnosed with renal disease, with a serum creatinine level \>=2.5 milligram per deciliter (mg/dL).
17. Participant has a platelet count \<100,000/ milliliter (mL) at screening (except for participants with type 2B VWD, whose platelet count\[s\] at screening will be evaluated taking into consideration historical trends in platelet counts and the investigator's medical assessment of the participant's condition).
18. Participant has cervical or uterine conditions causing menorrhagia or metrorrhagia (including infection, dysplasia).
19. In the judgment of the investigator, the participant has another clinically significant concomitant condition (eg, uncontrolled hypertension) that may pose additional risks for the participant.
20. Participant is identified by the investigator as being unable or unwilling to cooperate with study procedures.

Where this trial is running

Beijing and 6 other locations

• Peking Union Medical College Hospital — Beijing, China (Recruiting)
• Nanfang Hospital Southern Medical University — Guangzhou, China (Recruiting)
• Jinan Central Hospital — Jihan, China (Recruiting)
• Ruijin Hospital Shanghai Jiaotong University School of Medicine — Shanghai, China (Recruiting)
• The First Affiliated Hospital of Soochow University — Suzhou, China (Recruiting)
• Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences — Tianjin, China (Recruiting)
• Tongji Hospital Tongji Medical College Huazhong University of Science and Technology — Wuhan, China (Recruiting)

Study contacts

• Study coordinator: Takeda Contact

Conditions Von Willebrand Disease; Drug Therapy